Aesthetics Journal: Allergan And Intas Pharmaceuticals In Agreement After Trademark Debate

US pharmaceutical company Allergan has entered into a settlement with Indian manufacturer Intas Pharmaceuticals on the use of the trademarks ‘Botox’ and ‘BTX-A’ for botulinum toxin. The court order, which was issued on September 9 in the Delhi High Court, stated, “The defendant (Intas Pharmaceuticals) has acknowledged the plaintiff’s (Allergan) exclusive rights in respect of … Continue reading Aesthetics Journal: Allergan And Intas Pharmaceuticals In Agreement After Trademark Debate

Aesthetics Journal: Allergan Completes Kythera Acquisition

Global pharmaceutical company Allergan has announced that it has completed the acquisition of Kythera Biopharmaceuticals, Inc in a transaction valued at approximately $2.1 billion. The acquisition adds the treatment Kybella (deoxycholic acid), which became the first FDA approved non-surgical injection for submental fullness in April of this year, to Allergan’s portfolio. Brent Saunders, CEO and … Continue reading Aesthetics Journal: Allergan Completes Kythera Acquisition